ITRM vs CMPX vs AGEN vs CRL vs IQV

For growth investors, Agenus Inc.

(AGEN) is the stronger pick with 10. 4% revenue growth year-over-year, versus -100. 0% for Compass Therapeutics, Inc. (CMPX). IQVIA Holdings Inc. (IQV) offers the better valuation at 22. 8x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Compass Therapeutics, Inc. (CMPX) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Agenus Inc.

is actually cheaper at 1. 8x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, IQVIA Holdings Inc.

(IQV) delivered a total return of -23. 8%, compared to -99. 8% for Iterum Therapeutics plc (ITRM). Over 10 years, the gap is even starker: IQV returned +166. 5% versus ITRM's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), IQVIA Holdings Inc.

(IQV) is the lower-risk stock at 1. 33β versus Agenus Inc. 's 2. 72β — meaning AGEN is approximately 104% more volatile than IQV relative to the S&P 500. On balance sheet safety, Compass Therapeutics, Inc. (CMPX) carries a lower debt/equity ratio of 5% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Agenus Inc.

(AGEN) is pulling ahead at 10. 4% versus -100. 0% for Compass Therapeutics, Inc. (CMPX). On earnings-per-share growth, the picture is similar: Agenus Inc. grew EPS 100. 0% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, AGEN leads at 5. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

IQVIA Holdings Inc.

(IQV) is the more profitable company, earning 8. 3% net margin versus -69. 1% for Iterum Therapeutics plc — meaning it keeps 8. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IQV leads at 14. 0% versus -52. 0% for ITRM. At the gross margin level — before operating expenses — AGEN leads at 90. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Agenus Inc.

(AGEN) trades at 1. 8x forward P/E versus 16. 4x for Charles River Laboratories International, Inc. — 14. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CMPX: 518. 8% to $11. 20.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, IQVIA Holdings Inc.

(IQV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+166. 5% 10Y return). Agenus Inc. (AGEN) carries a higher beta of 2. 72 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IQV: +166. 5%, AGEN: -94. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.